Medical Information | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Related Articles
Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL
The Lymphoma Hub was pleased to speak to Grzegorz S. Nowakowski, Mayo Clinic, Rochester, US, who discussed the real-world experience of tafasitamab and lenalidomide for…
How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?
The Lymphoma Hub was pleased to speak to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked, How effective is the combination…
How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?
The Lymphoma Hub was pleased to speak to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked, How effective is the combination…
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Nivolumab for patients with ND FL: Results from the phase II 1st FLOR study
We summarize key results from the phase II 1st FLOR study evaluating the efficacy and safety of nivolumab priming followed by nivolumab + rituximab in…
NP30179 phase I/II study: Fixed-duration glofitamab in R/R MCL
We summarize key results from the phase I/II NP30179 study evaluating the efficacy and safety of fixed-duration glofitamab monotherapy in patients with R/R MCL, published…
NP30179 phase I/II study: Fixed-duration glofitamab in R/R MCL
We summarize key results from the phase I/II NP30179 study evaluating the efficacy and safety of fixed-duration glofitamab monotherapy in patients with R/R MCL, published…
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
EMA approves acalabrutinib combination for patients with previously untreated MCL
On May 6, 2025, the EMA granted approval to acalabrutinib in combination with bendamustine and rituximab for adult patients with previously untreated MCL who are…